Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC cut its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 0.8% during the third quarter, HoldingsChannel.com reports. The firm owned 2,661,878 shares of the company’s stock after selling 20,450 shares during the period. Geode Capital Management LLC’s holdings in Adaptive Biotechnologies were worth $13,632,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. The Manufacturers Life Insurance Company increased its position in shares of Adaptive Biotechnologies by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company’s stock worth $177,000 after purchasing an additional 2,710 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Adaptive Biotechnologies by 30.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company’s stock valued at $87,000 after acquiring an additional 4,000 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Adaptive Biotechnologies by 29.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company’s stock valued at $131,000 after acquiring an additional 5,826 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at $34,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ADPT has been the topic of several research reports. Piper Sandler upped their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. BTIG Research upped their target price on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $6.11 on Tuesday. The business’s 50-day moving average is $5.68 and its two-hundred day moving average is $4.80. The company has a market capitalization of $901.71 million, a P/E ratio of -4.56 and a beta of 1.49. Adaptive Biotechnologies Co. has a fifty-two week low of $2.28 and a fifty-two week high of $7.07.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.